Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 6/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL277740 | 0.97 | NR1I2 (0.51) | KCNH2NR1I2SCN9ACYP3A4SCN5A | |
| SCHEMBL277822 | 0.96 | NR1I2 (0.51) | KCNH2NR1I2SCN9ACYP3A4SCN5A | |
| SCHEMBL278057 | 0.96 | NR1I2 (0.51) | KCNH2NR1I2SCN9ACYP3A4SCN5A | |
| SCHEMBL278170 | 0.94 | NR1I2 (0.49) | KCNH2NR1I2SCN9ACYP3A4SCN5A | |
| SCHEMBL13621441 | 0.94 | KCNH2 (0.54) | KCNH2NR1I2SCN9ACYP3A4SCN5A | |
| SCHEMBL278073 | 0.93 | KCNH2 (0.52) | KCNH2NR1I2SCN9ACYP3A4SCN5A | |
| SCHEMBL862771 | 0.93 | NR1I2 (0.52) | KCNH2NR1I2SCN9ACYP3A4SCN5A | |
| SCHEMBL278024 | 0.92 | KCNH2 (0.50) | KCNH2NR1I2SCN9ACYP3A4SCN5A | |
| SCHEMBL278006 | 0.92 | KCNH2 (0.51) | KCNH2NR1I2SCN9ACYP3A4SCN5A | |
| SCHEMBL278187 | 0.92 | KCNH2 (0.51) | KCNH2NR1I2SCN9ACYP3A4SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280975-B1 | 7H-INDOLO[2,1-A][2]BENZAZEPINE-10-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2014-01-01 | — | — | EP | disclosed |
| US-8133884-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-13 | — | — | US | disclosed |
| US-8133884-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-13 | — | — | US | disclosed |
| US-20090280083-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-12 | — | — | US | disclosed |
| US-20090280083-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280083-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | KCNH2 3808/4885NR1I2 189/4885SCN9A 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.